These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20500042)

  • 1. Formulary decisions: then and now.
    Boucher BA
    Pharmacotherapy; 2010 Jun; 30(6 Pt 2):35S-41S. PubMed ID: 20500042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The formulary process from a risk management perspective.
    Raber JH
    Pharmacotherapy; 2010 Jun; 30(6 Pt 2):42S-47S. PubMed ID: 20500043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining the formulary status of quinolone antibiotics: one institution's approach.
    Nightingale CH; Lubowski T; On A; Quintiliani R
    Hosp Formul; 1992 May; 27(5):509-10, 513-4, 516. PubMed ID: 10128710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV; Wright-Etter PJ
    Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
    Choi Y; Navarro RP
    J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies in antimicrobial therapy: formulary decisions on third-generation cephalosporins.
    Barriere SL
    Am J Hosp Pharm; 1986 Mar; 43(3):625-9. PubMed ID: 3706317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulary considerations: the past, present, and future.
    Leber MB
    Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP490-SP491. PubMed ID: 29087661
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors that influence prescribing decisions.
    Schumock GT; Walton SM; Park HY; Nutescu EA; Blackburn JC; Finley JM; Lewis RK
    Ann Pharmacother; 2004 Apr; 38(4):557-62. PubMed ID: 14966259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.
    Skaer TL
    Hosp Formul; 1993 Jun; 28(6):577-84. PubMed ID: 10126586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of physician use of and attitudes toward closed formulary drug programs.
    Tootelian DH; Gaedeke RM
    Health Mark Q; 1991; 8(3-4):193-207. PubMed ID: 10111969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary decision-making considerations: COX-2 inhibitors.
    Shaya FT; Wong W; Shin JY; Martin L; Samant N
    Manag Care Interface; 2004 Nov; 17(11):29-36, 41. PubMed ID: 15573802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors that influence patient response to requests to change to a unified restrictive formulary.
    Smetana GW; Davis RB; Phillips RS
    J Gen Intern Med; 2004 Dec; 19(12):1212-9. PubMed ID: 15610332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.